Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction

S Battistelli1, M Billi, G Manasse

  • 1Istituto di Semeiotica Medica e Geriatria, University of Siena, Italy. battistelli@unisi.it

Angiology
|August 18, 1999
PubMed

Insights

Plasma endothelin-1 (ET-1) is elevated in acute myocardial infarction, especially with left ventricular failure. ET-1 levels correlate inversely with left ventricular ejection fraction, suggesting its utility as a disease marker and systolic function index.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Clinical Research

Background:

  • Acute myocardial infarction (AMI) is a leading cause of cardiovascular mortality.
  • Endothelin-1 (ET-1) is a potent vasoconstrictor peptide with potential roles in cardiovascular pathophysiology.
  • Left ventricular (LV) dysfunction is a common complication of AMI, impacting prognosis.

Purpose of the Study:

  • To investigate plasma ET-1 levels in patients with AMI, both complicated and uncomplicated by LV failure.
  • To assess the dynamic changes in ET-1 during the acute phase and recovery.
  • To correlate ET-1 levels with LV systolic function, specifically left ventricular ejection fraction (LVEF), and the impact of thrombolytic therapy.

Main Methods:

  • Plasma ET-1 was measured in 23 AMI patients (complicated/uncomplicated LV failure) and 14 controls on admission, days 2, 3, 5, and discharge.
  • LV function was assessed on discharge, with moderate to severe dysfunction defined as LVEF < 40%.
  • Correlation analyses were performed between ET-1, LV function, and thrombolytic treatment.

Main Results:

  • ET-1 was significantly elevated on admission in both uncomplicated (p < 0.01) and complicated (p < 0.001) AMI patients compared to controls.
  • In complicated patients, ET-1 remained elevated until discharge, unlike the uncomplicated group which normalized by day 5.
  • Plasma ET-1 showed a significant inverse correlation with LVEF (p < 0.001) on discharge, particularly in patients with LVEF < 40% (p < 0.001).
  • ET-1 levels were lower in patients receiving thrombolytic therapy (p < 0.05).

Conclusions:

  • Early elevation of ET-1 in AMI may reflect ischemia, stress, and hemodynamic impairment.
  • Sustained elevation of ET-1 in complicated AMI suggests its role in disease progression.
  • Plasma ET-1 serves as a valuable marker for disease severity and a reliable index of LV systolic function post-MI.

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...